- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CARDIO DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 20.08. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Cardio Diagnostics launches CLIA-certified laboratory in Iowa | 2 | Investing.com | ||
| 07.08. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 29.07. | Sika hebt IT auf C-Level und holt Jochen Werling als CDIO | 47 | CIO | ||
| 02.07. | Die drei Transformationen des Etex-CDIO Dirk Altgassen | 2 | CIO | ||
| 28.04. | UK.gov's DCMS to new CDIO: migrate from Google to Microsoft, overhaul ERP, build a team | 4 | The Register |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRINITY BIOTECH | 7,495 | -5,01 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| ONCONETIX | 0,435 | 0,00 % | SRX Global Inc: SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) | NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value... ► Artikel lesen | |
| QIAGEN | 42,820 | 0,00 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 |
Das Unternehmen CARDIO DIAGNOSTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARDIO DIAGNOSTICS HOLDINGS INC finden Sie auf Wallstreet Online.